WO2004017957A1 - Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee - Google Patents

Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee Download PDF

Info

Publication number
WO2004017957A1
WO2004017957A1 PCT/NZ2003/000047 NZ0300047W WO2004017957A1 WO 2004017957 A1 WO2004017957 A1 WO 2004017957A1 NZ 0300047 W NZ0300047 W NZ 0300047W WO 2004017957 A1 WO2004017957 A1 WO 2004017957A1
Authority
WO
WIPO (PCT)
Prior art keywords
arteries
copper
cardiomyopathy
diabetic
patient
Prior art date
Application number
PCT/NZ2003/000047
Other languages
English (en)
Inventor
Garth James Smith Cooper
John Richard Baker
Original Assignee
Protemix Corporation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protemix Corporation Limited filed Critical Protemix Corporation Limited
Priority to AU2003214725A priority Critical patent/AU2003214725A1/en
Publication of WO2004017957A1 publication Critical patent/WO2004017957A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

L'invention concerne des procédés pour réduire la teneur en cuivre, comprenant par exemple le traitement, la prévention, ou l'amélioration de dommages tissulaires, tels que, par exemple, des dommages tissulaires qui peuvent être provoqués par : (i) des troubles du muscle cardiaque (par exemple la cardiomyopathie ou la myocardite) tels que la cardiomyopathie idiopathique, la cardiomyopathie métabolique qui comprend la cardiomyopathie diabétique, la cardiomyopathie alcoolique, la cardiomyopathie induite par les médicaments, la cardiomyopathie ischémique, et la cardiomyopathie hypertensive ; (ii) des troubles athéromateux des vaisseaux sanguins principaux (maladie macrovasculaire), tels que l'aorte, les artères coronaires, les artères carotides, les artères cérébrovasculaires, les artères rénales, les artères iliaques, les artères fémorales, et les artères poplitées ; (iii) des troubles toxiques, induits par les médicaments, et métaboliques (tels que les troubles hypertensifs et/ou diabétiques) des petits vaisseaux sanguins (maladie microvasculaire) tels que les artérioles rétinales, les artérioles glomérulaires, le vasa nervorum, les artérioles cardiaques, et des lits capillaires associés de l'oeil, du rein, du coeur, du système nerveux central et périphérique ; (iv) la rupture de plaque des liaisons athéromateuses des vaisseaux sanguins principaux tels que l'aorte, les artères coronaires, les artères carotides, les artères cérébrovasculaires, les artères rénales, les artères iliaques, les artères fémorales, et les artères poplitées, (v) du diabète ou les complications du diabète.
PCT/NZ2003/000047 2002-08-20 2003-03-17 Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee WO2004017957A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003214725A AU2003214725A1 (en) 2002-08-20 2003-03-17 Preventing and/or treating cardiovascular disease and/or associated heart failure

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
NZ52089602 2002-08-20
NZ52089502 2002-08-20
NZ52089702 2002-08-20
NZ520897 2002-08-20
NZ520895 2002-08-20
NZ520896 2002-08-20

Publications (1)

Publication Number Publication Date
WO2004017957A1 true WO2004017957A1 (fr) 2004-03-04

Family

ID=31950468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2003/000047 WO2004017957A1 (fr) 2002-08-20 2003-03-17 Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee

Country Status (2)

Country Link
AU (1) AU2003214725A1 (fr)
WO (1) WO2004017957A1 (fr)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112763A2 (fr) * 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
US6951890B2 (en) 2002-03-08 2005-10-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
WO2006068516A1 (fr) * 2004-12-20 2006-06-29 Protemix Corporation Limited Dispositifs medicaux implantables revetus de composes chelateurs du cuivre ou contenant ces composes
WO2006104402A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions d'antagonistes du cuivre
WO2006104400A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions antagonistes du cuivre
WO2006104401A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions antagonistes du cuivre
EP1877801A1 (fr) * 2005-04-25 2008-01-16 Protemix Corporation Limited Thérapie et évaluation de la régulation par l'utilisation du cuivre
EP1948160A1 (fr) * 2005-11-09 2008-07-30 Protemix Corporation Limited Traitement de maladies liées aux mitochondries et amélioration de déficits métaboliques liés à l'âge
US7459446B2 (en) 1998-09-25 2008-12-02 John Richard Baker Treatment of diabetes with copper binding compounds
US7494990B2 (en) 2004-02-04 2009-02-24 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US7582796B2 (en) 2004-07-19 2009-09-01 Protemix Corporation Limited Synthesis of triethylenetetramines
EP2556834A1 (fr) * 2010-03-30 2013-02-13 Magnus TTM IC Utilisation therapeutique de tétrathiomolybdate
EP2578221A1 (fr) * 2011-10-04 2013-04-10 Magnus Intellectual Property Ltd. Utilisation thérapeutique de tétrathiomolybdate
US9339479B2 (en) 2002-08-20 2016-05-17 Philera New Zealand Limited Dosage forms and related therapies
US9498268B2 (en) 2010-07-06 2016-11-22 Luis Edgardo Ramos Maza Devices, systems, and methods for acetabulum repair
WO2017050271A1 (fr) * 2015-09-24 2017-03-30 Innolife Co., Ltd. Utilisation de trientine pour délivrer du cuivre à un tissu ischémique
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
US10988436B2 (en) 2018-05-04 2021-04-27 Orphalan S.A. Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147070A (en) * 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BERENSHTEIN ET AL.: "Roles of ferritin and iron in ischemic preconditioning of the heart", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 234-235, 2002, pages 283 - 292, XP002994679, DOI: doi:10.1023/A:1015923202082 *

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459446B2 (en) 1998-09-25 2008-12-02 John Richard Baker Treatment of diabetes with copper binding compounds
US7928094B2 (en) 1998-09-25 2011-04-19 Philera New Zealand Limited Treatment of diabetes with copper binding compounds
US6951890B2 (en) 2002-03-08 2005-10-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US8034799B2 (en) 2002-03-08 2011-10-11 Philera New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US8987244B2 (en) 2002-03-08 2015-03-24 Philera New Zealand Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
US9339479B2 (en) 2002-08-20 2016-05-17 Philera New Zealand Limited Dosage forms and related therapies
US9993443B2 (en) 2002-08-20 2018-06-12 Philera New Zealand Limited Dosage forms and related therapies
US10543178B2 (en) 2002-08-20 2020-01-28 Philera New Zealand Limited Dosage forms and related therapies
US11419831B2 (en) 2002-08-20 2022-08-23 Philera New Zealand Limited Dosage forms and related therapies
WO2004112763A2 (fr) * 2003-05-21 2004-12-29 Board Of Regents, The University Of Texas System Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
WO2004112763A3 (fr) * 2003-05-21 2005-09-09 Univ Texas Inhibition de la proteine kinase c-mu (pkd) dans le traitement de l'hypertrophie cardiaque et de l'insuffisance cardiaque
US7494990B2 (en) 2004-02-04 2009-02-24 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US7820669B2 (en) 2004-02-04 2010-10-26 Nycomed Gmbh 2-(piperidin-4-yl)-4,5-dihydro-2H-pyridazin-3-one derivatives as PDE4 inhibitors
US7582796B2 (en) 2004-07-19 2009-09-01 Protemix Corporation Limited Synthesis of triethylenetetramines
US9556123B2 (en) 2004-07-19 2017-01-31 Philera New Zealand Limited Synthesis of triethylenetetramines
US11795150B2 (en) 2004-07-19 2023-10-24 Philera New Zealand Limited Synthesis of triethylenetetramines
US8394992B2 (en) 2004-07-19 2013-03-12 Philera New Zealand Limited Synthesis of triethylenetetramines
US8912362B2 (en) 2004-07-19 2014-12-16 Philera New Zealand Limited Synthesis of triethylenetetramines
WO2006068516A1 (fr) * 2004-12-20 2006-06-29 Protemix Corporation Limited Dispositifs medicaux implantables revetus de composes chelateurs du cuivre ou contenant ces composes
WO2006104401A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions antagonistes du cuivre
WO2006104400A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions antagonistes du cuivre
WO2006104402A1 (fr) * 2005-03-26 2006-10-05 Protemix Corporation Limited Compositions d'antagonistes du cuivre
EP1877801A4 (fr) * 2005-04-25 2009-03-18 Protemix Corp Ltd Thérapie et évaluation de la régulation par l'utilisation du cuivre
EP1877801A1 (fr) * 2005-04-25 2008-01-16 Protemix Corporation Limited Thérapie et évaluation de la régulation par l'utilisation du cuivre
EP1948160A4 (fr) * 2005-11-09 2013-07-10 Protemix Corp Ltd Traitement de maladies liées aux mitochondries et amélioration de déficits métaboliques liés à l'âge
EP1948160A1 (fr) * 2005-11-09 2008-07-30 Protemix Corporation Limited Traitement de maladies liées aux mitochondries et amélioration de déficits métaboliques liés à l'âge
EP2556834A1 (fr) * 2010-03-30 2013-02-13 Magnus TTM IC Utilisation therapeutique de tétrathiomolybdate
CN103096903A (zh) * 2010-03-30 2013-05-08 马格纳斯Ttmic公司 四硫钼酸的治疗用途
US10478455B2 (en) 2010-03-30 2019-11-19 Ucl Business Ltd Therapeutic use of tetrathiomolybdate
US9498268B2 (en) 2010-07-06 2016-11-22 Luis Edgardo Ramos Maza Devices, systems, and methods for acetabulum repair
EP2578221A1 (fr) * 2011-10-04 2013-04-10 Magnus Intellectual Property Ltd. Utilisation thérapeutique de tétrathiomolybdate
US10369108B2 (en) 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
EP3352743A4 (fr) * 2015-09-24 2019-07-03 Innolife Co., Ltd. Utilisation de trientine pour délivrer du cuivre à un tissu ischémique
US11033579B2 (en) 2015-09-24 2021-06-15 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue
AU2016328156B2 (en) * 2015-09-24 2022-03-17 Innolife Co., Ltd. Use of trientine to deliver copper to ischemic tissue
EA037045B1 (ru) * 2015-09-24 2021-01-29 Иннолайф Ко., Лтд. Применение триентина для доставки меди в ишемизированную ткань
WO2017050271A1 (fr) * 2015-09-24 2017-03-30 Innolife Co., Ltd. Utilisation de trientine pour délivrer du cuivre à un tissu ischémique
US10988436B2 (en) 2018-05-04 2021-04-27 Orphalan S.A. Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
US11072577B2 (en) 2018-05-04 2021-07-27 Orphalan S.A. Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
US11117855B2 (en) 2018-05-04 2021-09-14 Orphalan S.A. Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use

Also Published As

Publication number Publication date
AU2003214725A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
US8987244B2 (en) Preventing and/or treating cardiovascular disease and/or associated heart failure
WO2004017957A1 (fr) Prevention et/ou traitement de maladies cardio-vasculaires et/ou insuffisance cardiaque associee
JP2005533003A5 (fr)
US7928094B2 (en) Treatment of diabetes with copper binding compounds
WO2003075910A1 (fr) Prevention et/ou traitement d'une maladie vasculaire, d'une cardiomyopathie et/ou d'une defaillance cardiaque associee
US20060100278A1 (en) Dosage forms and related therapies
JP2002543118A (ja) ペントキシフィリン、ピオグリタゾンおよびメトフォルミンは、後期糖化最終生成物（ａｇｅ）の形成の阻害剤である
Bernhardt Coordination chemistry and biology of chelators for the treatment of iron overload disorders
US20100004303A1 (en) Treatment of endocrine dysfunction using iron chelators
US20180271807A1 (en) Meglumine in Combination with Another Therapeutic
NZ545724A (en) Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
CA2828595C (fr) Utilisation de tetraamines chelatant le cuivre destines au traitement de maladies cardiovasculaires et d'insuffisance cardiaque
JP2023500060A (ja) フェロポーチン阻害剤（ｖｉｔ－２７６３）を用いる鎌状赤血球症を治療するための方法及び組成物
Al-Rousan Efficacy of Deferasirox in Preventing Complications of Iron Overload in the Iron Overloaded Gerbil
Vlachodimitropoulou Koumoutsea Novel approaches to iron chelation therapy: novel combinations and novel compounds
Verma Effect of metformin treatment on isolated cardiac function and blood pressure in diabetic and hypertensive rats
NZ539695A (en) Dosage forms and related therapies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP